{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.71","value":"3.0"}]}],"title":"Best change"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.61","value":"-10.7"}]}],"title":"Worst change"}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"}],"units":"Participants"}],"description":"The change in Karnofsky performance status was reported as the best (highest change score) and worst (lowest change score) change from baseline using the Karnofsky performance criteria. The Karnofsky score classified participants according to their functional impairment. Scores are on a scale from 0-100, the lower the score, the worse the survival for most serious illnesses.","dispersionType":"Standard Deviation","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"OG000","title":"Idelalisib"}],"paramType":"MEAN","populationDescription":"Participants in the ITT Analysis Set with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline to End of Treatment (up to 81 months)","title":"Change in Karnofsky Performance Status","type":"SECONDARY","unitOfMeasure":"units on a scale"}